Highlights • A novel IPV vaccine was developed from attenuated Sabin poliovirus strains.• The vaccine was generally well tolerated in adults, toddlers and infants.• The vaccine was immunogenic as a… Click to show full abstract
Highlights • A novel IPV vaccine was developed from attenuated Sabin poliovirus strains.• The vaccine was generally well tolerated in adults, toddlers and infants.• The vaccine was immunogenic as a booster in previously polio-vaccinated toddlers.• The vaccine was insufficiently immunogenic from 6 weeks of age in the EPI schedule.• There was evidence of interference of the immune response by maternal antibodies.
               
Click one of the above tabs to view related content.